Advertisement

Topics

CardioComm Solutions' (TSXV: EKG) HeartCheck(TM) Device Enters Final FDA Review Phase

01:00 EST 29 Jan 2019 | InvestorIdeas

Toronto, Ontario - January 29, 2019 (Newsfile Corp.) (Investorideas.com Newswire) CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, confirms it has completed a request for additional information from the US Food and Drug Administration ("FDA") for the Company's premarket notification 510(k)

Original Article: CardioComm Solutions' (TSXV: EKG) HeartCheck(TM) Device Enters Final FDA Review Phase

NEXT ARTICLE

More From BioPortfolio on "CardioComm Solutions' (TSXV: EKG) HeartCheck(TM) Device Enters Final FDA Review Phase"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...